News ImmuCell Corporation

Stocks

ICCC

US4525253062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 13/06/2026 +04			5-day change	1st Jan Change
9.680 ^USD	-0.62%		+0.73%	+57.40%

05-15	ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026
05-15	ImmuCell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

All News

Mentions Relevance

05-15	ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026
05-15	ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026	AQ
05-15	ImmuCell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-09	ImmuCell, Norbrook enter settlement deed on May 8, 2026 - SEC filing	RE
05-08	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026	AQ
04-22	ImmuCell : Corporate Presentation (Investor Relations April 2026 Final)	PU
04-14	ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors	AQ
04-14	ImmuCell Corporation Announces Board Changes	CI
04-09	ImmuCell Q1 Sales Jump; Shares Rise After Hours	MT
04-09	ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results	AQ
04-09	Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Firs Quarter of 2026	CI
03-19	Immucell Corporation Announces Changes to Its Board, Effective April 1, 2026	CI
03-19	ImmuCell : 03-18-26 – ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board	PU
03-19	ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board	AQ
03-05	ImmuCell Corporation, Q4 2025 Earnings Call, Mar 05, 2026
03-05	ImmuCell Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-05	ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025	AQ
02-18	ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025	AQ
02-10	Steven A. Rosgen and Bryan K. Gathagan Have Decided Not to Seek Re-Election as Directors of ImmuCell Corporation	CI
01-09	ImmuCell Corporation, Q4 2025 Sales/ Trading Statement Call, Jan 09, 2026
01-09	ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025	AQ
01-09	Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-07	ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus	AQ
12-24	ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter	DJ
12-24	ImmuCell pauses investment in Re-Tain	RE